Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail

📈 Needham analyst Ami Fadia upgraded Biogen (BIIB) to Buy, highlighting pipeline potential and business stabilization.

💰 Biogen shares closed at $200.05 with an average analyst price target of $219.52, offering 9.4% upside.

🔍 Mizuho Securities maintains a Buy rating on Biogen with a specific price target of $221.00.

🚀 H.C. Wainwright analyst Andrew Fein maintained a Strong Buy rating for Palvella Therapeutics (PVLA).

🎯 Palvella shares closed at $108.81 with an average price target of $234.89, implying 119.9% upside.

📊 Mizuho Securities reiterated a Buy rating for Palvella Therapeutics with a $240.00 price target.

Bullish Signals
  • Needham analyst Ami Fadia upgraded Biogen to Buy, specifically citing the company's pipeline potential and stabilizing core business as key drivers.
  • Biogen has a moderate buy consensus rating with an average price target of $219.52, suggesting a 9.4% upside from current levels.
  • Palvella Therapeutics holds a strong buy consensus rating with an average price target of $234.89, representing a substantial 119.9% upside potential.
  • Mizuho Securities maintains a Buy rating on Biogen with a price target of $221.00, reinforcing positive analyst sentiment.
  • H.C. Wainwright analyst Andrew Fein maintained a Strong Buy rating for Palvella Therapeutics with a high price target of $270.00.
Full Analysis
Analysts have expressed bullish sentiment regarding Biogen (BIIB) and Palvella Therapeutics (PVLA), with recent upgrades driving optimism in the healthcare sector. Needham analyst Ami Fadia upgraded Biogen to Buy, citing pipeline potential and a stabilizing core business, while H.C. Wainwright's Andrew Fein maintained a Strong Buy rating for Palvella Therapeutics. Biogen shares closed at $200.05 last Friday, with analysts projecting an average price target of $219.52, representing a 9.4% upside. Mizuho Securities also maintains a Buy rating on Biogen with a $221.00 target. The consensus suggests moderate buy sentiment for the company based on current market conditions and future growth prospects. Palvella Therapeutics shares closed at $108.81, with H.C. Wainwright setting a price target of $270.00. The general street consensus indicates a Strong Buy rating for Palvella, with an average price target of $234.89 and a significant 119.9% upside potential. Mizuho Securities reiterated its Buy rating with a $240.00 target in a report from May 27.